Compare VanEck Rare Earth/Strategic Metals (REMX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Stryker Corporation — how do they compare? VanEck Rare Earth/Strategic Metals trades at $61 (market cap $1.75B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 60.7× VanEck Rare Earth/Strategic Metals's market cap, and Stryker Corporation pays a 1.27% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and Stryker Corporation for 21 Days on average.
| REMX | SYK | |
|---|---|---|
Market Cap | $1.75B | $106.24B |
Volume | 930,523 | 2,982,001 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $388.35 |
52-Week Low | $60.58 | $269.75 |
Typical Hold Time | 50 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.97, down 1.47% with a bearish technical outlook. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 14 suggest potential oversold conditions. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, with Bank of America increasing its stake by 72.1% in the latest quarter.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China exposure. While geopolitical trends support long-term demand, current technical weakness and sector-specific risks warrant caution. The reshoring trade provides structural tailwinds, but investors should be prepared for elevated price swings.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
